Back to search

Japan· JP-2339004C1036

β-ガラクトシダーゼ(ペニシリウム)

A medicinal product containing β-ガラクトシダーゼ(ペニシリウム), registered in Japan by 高田製薬, on the national reimbursement list.

On Japan’s NHI price list

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedβ-ガラクトシダーゼ(ペニシリウム)ATC—REGISTER NO.JP-2339004C1036PACKS LISTED0CHECKEDSeptember 25, 2026

The record

At a glance

MHLW / PMDA (Japan)
Active substance
β-ガラクトシダーゼ(ペニシリウム)
Manufacturer
高田製薬
Country
Japan (JP)
ATC code
—
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/fdd1a76e-3504-42b2-b554-f080551273a6
GET /v1/drugs/fdd1a76e-3504-42b2-b554-f080551273a6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "50%1g",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "2339004C1036",
  "category": "内用薬",
  "price_yen": 51.7,
  "generic_name": "β-ガラクトシダーゼ(ペニシリウム)",
  "product_name_jp": null,
  "therapeutic_class": "2339",
  "transitional_expiry": null
}

See everything about β-ガラクトシダーゼ(ペニシリウム).

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.